3D Bioprinting Market Size, Share, and Growth Forecast 2026 - 2033

3D Bioprinting Market by Component (3D Bioprinters, Bioinks, Scaffolds, Software, Others), Technology (Extrusion-Based, Inkjet-Based, Laser-Assisted, Others), Application (Tissue Engineering, Drug Testing, Regenerative Medicine, Organ Printing, Disease Research, Others), End-User (Pharmaceutical Companies, Biotechnology Companies, Research Institutes, Hospitals, Others), and Regional Analysis, 2026 - 2033

ID: PMRREP3255
Calendar

November 2026

199 Pages

Author : Abhijeet Surwase

3D Bioprinting Market Size and Trends Analysis

The global 3D bioprinting market is expected to be valued at US$ 3.1 billion in 2026 and is projected to reach US$ 5.9 billion by 2033, growing at a CAGR of 9.6% between 2026 and 2033.

Market growth is primarily driven by the persistent shortage of transplantable organs and the pharmaceutical industry's increasing demand for human-relevant tissue models. The Organ Procurement and Transplantation Network (OPTN) reports more than 100,000 patients on the U.S. transplant waiting list, while drug developers face clinical failure rates of roughly 90%, highlighting the limitations of conventional preclinical models. Regulatory developments further reinforce this demand.

The FDA Modernization Act 2.0, signed in December 2022, removed the mandatory animal-testing requirement for new drugs, and the U.S. Food and Drug Administration (FDA) announced a roadmap in April 2025 to further reduce animal studies. Falling bioprinter prices and expanding bioink portfolios are also broadening adoption across research and clinical settings.

Key Industry Highlights

  • Leading Region: North America is likely to lead the 3D bioprinting market with around 39% share in 2026, supported by substantial public research funding, a persistent organ shortage, and a well-established biotechnology ecosystem. The presence of leading bioprinting companies, pharmaceutical innovators, and regulatory support for non-animal testing methods further strengthens the region's market position.
  • Fastest-Growing Region: Asia Pacific represents the fastest-growing regional market, expanding at an estimated CAGR of 11.5% from 2026 to 2033, driven by aging populations, rising healthcare expenditure, supportive regenerative medicine policies, and increasing biotechnology investments across China, Japan, India, and South Korea. Growing local manufacturing of bioprinters and bioinks is also improving product accessibility and affordability.
  • Leading Segment: 3D bioprinters are the leading component segment, holding an estimated 34% market share in 2026, supported by increasing investments in bioprinting infrastructure, expanding research activities, and the growing adoption of commercial bioprinting platforms across academic and pharmaceutical laboratories. Extrusion-based technology leads the technology category, while drug testing and research institutes dominate their respective categories.
  • Fastest-Growing Segment: Bioinks are the fastest-growing component segment, expanding at an estimated CAGR of 11.8% from 2026 to 2033, driven by rising demand for tissue-specific, xeno-free, and GMP-grade biomaterials. Increasing pharmaceutical research activities and clinical regenerative medicine programs further support demand for advanced bioinks and recurring consumable purchases.
  • Key Market Opportunity: Growing pharmaceutical partnerships and clinical regenerative medicine programs, supported by the FDA's April 2025 roadmap to reduce animal testing, create an incremental opportunity of US$ 2.8 billion for bioprinter, bioink, and tissue model providers. Expanding hospital-based point-of-care manufacturing and increasing demand for human-relevant drug testing models create additional revenue opportunities for market participants.

See exactly what you're buying — Before you spend a dollar.

Get a free sample copy of our market report: data, tables, charts, research depth, analyst insights, and relevance of our research - all in hand before you commit.

Market Dynamics

Drivers - Persistent Organ Shortage and Rising Demand for Regenerative Therapies

The widening gap between organ supply and demand represents one of the key growth drivers for the 3D bioprinting market. According to the Health Resources and Services Administration (HRSA), more than 100,000 people in the U.S. are on the national transplant waiting list, with about 17 deaths reported each day among patients awaiting transplants. Globally, the WHO Global Observatory on Donation and Transplantation recorded approximately 157,000 solid organ transplants in 2022, meeting less than 10% of estimated global demand, according to the World Health Organization (WHO).

3D bioprinting offers a potential pathway for developing patient-specific skin, cartilage, bone, and, eventually, vascularized organs using a patient's own cells, reducing dependence on donor organs and the risk of immune rejection. Aging populations further reinforce this demand, as the United Nations projects the global population aged 65 and above to reach about 1.6 billion by 2050.

Regulatory Shift Toward Human-Relevant Models and Rising Pharmaceutical R&D

Regulatory developments are increasingly encouraging pharmaceutical developers to adopt human-relevant, cell-based testing models, positioning bioprinted tissues as promising alternatives to conventional preclinical testing methods. The FDA Modernization Act 2.0, signed in December 2022, allows sponsors to use non-animal methods to support investigational applications. In April 2025, the U.S. Food and Drug Administration (FDA) announced a roadmap to reduce animal testing, particularly in monoclonal antibody development.

The National Institutes of Health (NIH) also signaled a similar priority for human-based research technologies during the same month. The economic rationale for adopting alternative testing methods is substantial, as Deloitte estimated the average cost of developing a new drug asset at about US$ 2.3 billion in 2022, while research published in Acta Pharmaceutica Sinica B reports that roughly 90% of clinical drug candidates fail. Bioprinted liver, tumor, and skin models developed by companies such as Organovo Holdings, Inc. and Inventia Life Science provide pharmaceutical developers with opportunities to generate earlier and potentially more predictive preclinical data, supporting more informed drug development decisions.

Restraints - Technical Barriers in Vascularization, Cell Viability, and Scale-Up

Developing bioprinted tissues that maintain long-term cell viability and biological functionality remains a significant technical challenge. Oxygen and nutrients diffuse only about 100–200 micrometers into tissue, making the integration of perfusable vascular networks essential for thicker constructs. However, existing bioprinting technologies continue to face challenges in reproducing complex vascular structures at the capillary level. Cell viability after printing also varies considerably across technologies.

A review by Murphy and Atala, published in Nature Biotechnology in 2014, reported viability rates of approximately 40–80% for extrusion-based printing, compared with above 85% for inkjet and above 95% for laser-assisted printing. Solid organs also contain billions of cells arranged in highly specialized architectures, while printing speed, tissue maturation time, and manufacturing reproducibility continue to constrain commercial scale-up. To date, no bioprinted solid organ has achieved routine clinical transplantation, limiting near-term commercial applications and keeping hospitals and investors cautious about the technology's clinical readiness. These limitations continue to restrict broader adoption beyond research and preclinical applications.

Regulatory Uncertainty and High Equipment and Material Costs

Bioprinted products combine living cells, biomaterials, and printing devices, creating complex regulatory classifications and approval requirements. In the U.S., the FDA issued guidance on additive-manufactured medical devices in 2017, while bioprinted constructs containing living cells are generally subject to biologics oversight by the Center for Biologics Evaluation and Research (CBER), depending on their intended use and regulatory classification. In Europe, relevant products are governed by the Advanced Therapy Medicinal Products (ATMP) Regulation (EC) No. 1394/2007 and the Medical Device Regulation (EU) 2017/745, depending on product classification.

Standards for bioink quality, printing validation, and batch release are still evolving, increasing regulatory complexity and extending product development and approval timelines. High equipment and material costs create an additional barrier to adoption. Advanced bioprinters often exceed US$ 100,000, while high-grade bioinks, growth factors, and primary cells involve substantial recurring expenditure and batch-to-batch variability. Consequently, universities and smaller biotechnology companies frequently delay equipment purchases or rely on shared research facilities, limiting direct investment in advanced bioprinting infrastructure.

Opportunities - Bioinks and Advanced Biomaterials as the Fastest-Growing Segment

Expanding bioinks, which represent the fastest-growing component segment, creates immense opportunities. The segment also offers recurring revenue opportunities that complement one-time bioprinter sales. Market demand is shifting from generic hydrogels toward tissue-specific materials, including decellularized extracellular matrix, gelatin methacryloyl, and recombinant human collagen. CollPlant Biotechnologies Ltd. produces plant-derived recombinant human collagen and has collaborated with Stratasys Ltd. on bioprinted breast implants and with AbbVie on dermal fillers, demonstrating the commercial potential of advanced biomaterial platforms across therapeutic and research applications.

CELLINK, part of BICO Group AB, and Merck KGaA offer broad bioink and reagent portfolios, strengthening customer retention through validated printer-material combinations. Companies offering xeno-free, GMP-grade, and animal-component-free bioinks are positioned to capitalize on increasing demand as clinical programs advance toward regulatory submissions. Rising adoption of tissue-specific materials and growing consumption across research and clinical development workflows further strengthen the segment's revenue potential.

Pharmaceutical Partnerships and Clinical Regenerative Programs

Pharmaceutical partnerships and clinical regenerative medicine programs represent another significant growth opportunity for the 3D bioprinting market. Large pharmaceutical developers are increasingly investing in bioprinting technologies to advance cell therapies and develop more predictive disease models. In April 2023, Aspect Biosystems Ltd. and Novo Nordisk signed a collaboration involving US$ 75 million in upfront funding and up to US$ 650 million per product in milestone payments to develop bioprinted tissue therapeutics for diabetes and obesity.

United Therapeutics Corporation also continues its collaboration with 3D Systems Corporation on printed lung scaffolds as part of its organ manufacturing strategy. Regenerative medicine is the fastest-growing application segment, supported by point-of-care manufacturing frameworks and hospital-based bioprinting programs for skin, cartilage, and bone. These developments are creating opportunities for technology providers offering integrated solutions that combine bioprinters, bioinks, software, and regulatory support.

Companies with comprehensive clinical bioprinting platforms are positioned to secure long-term pharmaceutical partnerships, collaborative development agreements, and milestone-based revenue as regenerative medicine programs progress toward commercialization.

Category-wise Analysis

Component Insights

3D bioprinters lead the component category, accounting for an estimated 34% share of the market in 2026. Printers serve as the primary equipment required for bioprinting workflows, making them an essential initial investment for laboratories before the adoption of complementary products such as bioinks, scaffolds, and software. Commercial platforms such as CELLINK BIO X from BICO Group AB, Allevi systems owned by 3D Systems Corporation, printers from RegenHU Ltd., and the RASTRUM platform from Inventia Life Science Pty Ltd. have improved accessibility for academic and industrial users.

Public research funding, including the National Institutes of Health (NIH) annual budget of roughly US$ 47 billion and the EUR 95.5 billion Horizon Europe program, further supports instrument procurement. The relatively high unit price of bioprinters, combined with an expanding installed base, reinforces the segment's leading position.

Bioinks represent the fastest-growing component segment, driven by increasing demand for tissue-specific biomaterials, xeno-free formulations, and GMP-grade materials for advanced tissue engineering and regenerative medicine applications. Growing pharmaceutical research activity and the expansion of clinical bioprinting programs further increase demand for specialized bioinks and recurring consumable purchases.

Technology Insights

Extrusion-based bioprinting leads the technology category, accounting for an estimated 46% share of the market in 2026. The technology deposits continuous filaments of bioink through a nozzle using pneumatic, piston, or screw-based pressure. It accommodates a wide range of bioink viscosities, high cell densities, and multiple materials within a single printing process. Relatively affordable equipment and straightforward maintenance make this technology suitable for universities, research institutes, and hospital laboratories. A 2014 review published in Nature Biotechnology by Murphy and Atala identified extrusion-based bioprinting as a versatile approach for developing large, structurally supportive tissues, including cartilage, bone, and vascular grafts. Most commercial printers from CELLINK, RegenHU Ltd., and ROKIT Healthcare, Inc. incorporate extrusion-based printing systems, supporting the technology's widespread adoption.

Laser-assisted bioprinting is the fastest-growing technology segment, with an estimated CAGR of 10.8% through 2033. Growth is driven by its high printing resolution, precise cell placement, and high post-printing cell viability, which exceeds 95% in certain applications. Increasing demand for complex tissue structures and advanced research models further supports adoption.

Application Insights

Drug testing is the leading application segment, accounting for an estimated 31% share of the market in 2026. Bioprinted liver, kidney, skin, and tumor tissues reproduce cell-cell interactions more effectively than conventional two-dimensional cultures, providing pharmaceutical developers with more relevant toxicity and drug-response data during preclinical testing. Research published in Acta Pharmaceutica Sinica B highlights the roughly 90% clinical failure rate of drug candidates, with inadequate efficacy and unmanageable toxicity representing major reasons for failure. This creates demand for more predictive preclinical testing models.

The FDA Modernization Act 2.0 and the FDA roadmap announced in April 2025 further support the adoption of non-animal testing methods in drug development. Companies such as Organovo Holdings, Inc. and Inventia Life Science Pty Ltd. offer bioprinted tissue models for toxicity assessment and drug screening. Cosmetic companies also use bioprinted skin models to support compliance with the European Union's ban on animal testing for cosmetics. Repeated testing across multiple drug candidates and increasing outsourcing of preclinical studies sustain demand for this application.

End-User Insights

Research institutes represent the leading end-user segment, accounting for an estimated 38% share of the market in 2026. Universities, government laboratories, and academic medical centers were among the earliest adopters of bioprinting technology and continue to account for substantial purchases of bioprinters and bioinks. Procurement is supported by large public research programs, including the National Institutes of Health (NIH), which invests roughly US$ 47 billion annually in research, and the European Union's Horizon Europe program, which funds biofabrication and tissue engineering projects.

The Advanced Regenerative Manufacturing Institute (ARMI), launched in 2016 with US$ 80 million in funding from the U.S. Department of Defense, further supports biofabrication development. Research activities focused on tissue engineering, disease modeling, and printing technology development sustain demand for flexible, open-architecture platforms from suppliers such as CELLINK and RegenHU Ltd.

Pharmaceutical companies represent the fastest-growing end-user segment, with an estimated CAGR of 11.0% through 2033. Growth is driven by increasing adoption of bioprinted tissue models for drug discovery, toxicity testing, and preclinical evaluation. Pharmaceutical partnerships with bioprinting developers and rising investment in regenerative medicine further support segment expansion.

Not every business fits the same mold. Your research shouldn't either.

Connect with the team for a customization and get a one-of-a-kind report scoped to your niche — The insights your competitors won't have access to.

Regional Analysis

North America 3D Bioprinting Market Trends and Insights

North America is expected to lead the global 3D bioprinting market by holding around 39% share in 2026. The region benefits from substantial public research funding, a strong concentration of biotechnology and medical device companies, and regulatory initiatives supporting alternatives to animal testing. Key market trends include increasing adoption of bioprinted tissues for pharmaceutical drug screening following the FDA Modernization Act 2.0, early clinical development programs involving skin, cartilage, and bone, and rising venture capital investment in regenerative medicine start-ups.

The Advanced Regenerative Manufacturing Institute (ARMI) and the National Science Foundation support the transition of laboratory-based technologies toward scalable biofabrication processes. Canada further contributes through university research programs and companies such as Aspect Biosystems Ltd. in Vancouver, which has secured major pharmaceutical partnerships and strengthened the regional bioprinting ecosystem.

U.S. 3D Bioprinting Market Size

The U.S. 3D bioprinting market is estimated at US$ 950 million in 2026, representing roughly 87% of regional market revenue. Market growth is supported by a substantial organ shortage, with more than 100,000 patients on the transplant waiting list and about 17 deaths daily, according to the Health Resources and Services Administration (HRSA). Federal research funding through the National Institutes of Health (NIH) and the U.S. Department of Defense, alongside the presence of companies such as 3D Systems Corporation, Organovo Holdings, Inc., and United Therapeutics Corporation, strengthens domestic innovation.

Increasing regulatory acceptance of human-relevant testing models and growing interest in hospital-based point-of-care manufacturing create additional growth opportunities. Cell and gene therapy developers, academic medical centers, and medical device manufacturers also represent an established customer base. Collaboration among hospitals, universities, and start-ups in biotechnology clusters such as Boston and San Diego further accelerates the development and commercialization of bioprinted tissues.

Europe 3D Bioprinting Market Trends and Insights

Europe is projected to hold about 27% share of the 3D bioprinting market in 2026, supported by strong academic research capabilities, public funding, and regulatory initiatives promoting alternatives to animal testing. Horizon Europe, with a budget of approximately EUR 95.5 billion for 2021-2027, funds several biofabrication and tissue engineering projects, while Directive 2010/63/EU promotes the principles of replacing, reducing, and refining animal testing. The European Medicines Agency (EMA) regulates qualifying bioprinted therapies under the advanced therapy medicinal products (ATMP) framework, providing an established regulatory pathway for relevant products.

Key regional trends include the expansion of bioprinting companies in Sweden, Switzerland, and France, increasing collaborations between hospitals and universities, and rising adoption of bioprinted skin models for cosmetic and pharmaceutical testing. Regional industry participants include BICO Group AB in Sweden, RegenHU Ltd. in Switzerland, and Poietis in France.

Germany 3D Bioprinting Market Size

Germany represents the largest European market for 3D bioprinting, with market size is estimated at US$ 200 million in 2026. Research institutions such as the Fraunhofer Society, particularly its Institute for Interfacial Engineering and Biotechnology (IGB), and universities with established tissue engineering programs support demand for bioprinting equipment. Merck KGaA, headquartered in Darmstadt, reported group sales of about EUR 21.2 billion in 2024 and supplies materials used in cell culture and bioprinting applications.

A strong medical technology and orthopedic industry, combined with federal funding for animal-free research methods, creates opportunities for bioprinted implants and testing models. Public research grants and university-industry collaborations further support commercialization, while demand from contract testing laboratories generates recurring consumption of bioinks and other consumables across the country.

U.K. 3D Bioprinting Market Size

The U.K. 3D bioprinting market is estimated at US$ 150 million in 2026. Universities in Nottingham, Manchester, Oxford, and Cambridge maintain active bioprinting research programs, while the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) funds the development of human-relevant tissue models. The Cell and Gene Therapy Catapult supports the scale-up of advanced therapies, while the Medicines and Healthcare products Regulatory Agency (MHRA) introduced a point-of-care manufacturing framework in 2025, supporting the development of hospital-based personalized tissue products.

Strong academic research output, active start-up formation, and research council funding sustain demand for bioprinters, bioinks, and tissue models. Access to global pharmaceutical customers further supports the commercialization of domestic technologies and the expansion of industry partnerships.

France 3D Bioprinting Market Size

France accounts for an estimated 16% of the European market revenue. Poietis, a French bioprinting company, develops laser-assisted bioprinted skin models and has advanced these technologies toward clinical evaluation in collaboration with public hospitals in Paris. Cosmetic companies such as L'Oréal use reconstructed and bioprinted skin models as alternatives to animal testing.

The France 2030 investment plan earmarks about EUR 7.5 billion for health innovation, while research organizations such as Inserm support tissue engineering and regenerative medicine research. These developments create growth opportunities across dermatology, orthopedics, and cosmetic safety testing. Public hospital networks and national funding for biotherapies further support translational research, while collaborations with cosmetic and pharmaceutical companies generate recurring demand for bioprinted tissue models.

Asia Pacific 3D Bioprinting Market Trends and Insights

Asia Pacific represents the fastest-growing regional market, growing at an estimated CAGR of 11.5% during 2026 - 2033. Expanding healthcare expenditure, aging populations, and government support for biotechnology and regenerative medicine are driving regional adoption. In China, universities and biotechnology companies are investing in bioprinted bone, cartilage, and skin models as part of broader healthcare innovation initiatives. Domestic manufacturers are also introducing lower-cost bioprinters and bioinks, improving accessibility for research institutions. South Korea contributes through companies such as ROKIT Healthcare, Inc., which develops bioprinting-based skin regeneration technologies for diabetic foot ulcers.

Key regional trends include increasing domestic production of bioprinting equipment, expanding medical tourism, growing partnerships between hospitals and research institutes, and regulatory modernization in Japan, South Korea, and India. These developments are strengthening the regional bioprinting ecosystem and supporting its position as a major growth market.

India 3D Bioprinting Market Size

India's 3D bioprinting market is estimated at US$ 500 million in 2026. Despite its relatively small market size, India represents a high-growth country market, supported by increasing interest in tissue engineering and regenerative medicine. The National Organ and Tissue Transplant Organisation (NOTTO) reported more than 15,000 transplants in 2022, highlighting the gap between organ transplantation capacity and medical demand. The BioE3 Policy, approved in August 2024, promotes biotechnology innovation and biomanufacturing, while the Department of Biotechnology funds regenerative medicine research.

Domestic companies such as Next Big Innovation Labs are developing cost-effective bioprinters, improving access for universities and research institutions. Rising healthcare expenditure, a large pool of trained life sciences graduates, and expanding hospital networks further support domestic demand. Government-backed incubators also contribute to the development of early-stage biofabrication start-ups across the country.

Japan 3D Bioprinting Market Size

Japan's 3D bioprinting market is estimated at 110 million in 2026. The country benefits from established stem cell research capabilities, recognized by the 2012 Nobel Prize awarded to Shinya Yamanaka, and a regulatory framework that supports regenerative medicine development. Japan's Pharmaceuticals and Medical Devices Act of 2014 introduced a conditional approval pathway for regenerative medical products, supporting commercialization opportunities for advanced tissue engineering technologies. Cyfuse Biomedical K.K. commercializes bioprinters based on the Kenzan method, which uses cell aggregates to develop tissue structures.

With about 29% of Japan's population aged 65 or older, according to the Ministry of Internal Affairs and Communications, the growing prevalence of age-related conditions is increasing demand for regenerative medicine research targeting cartilage, bone, and vascular disorders. Pharmaceutical companies, academic research institutes, and domestic bioprinter manufacturers further support the adoption of bioprinters and bioinks across research and development activities. Government funding through the Japan Agency for Medical Research and Development (AMED) also strengthens research capabilities and supports the translation of bioprinting technologies into commercial applications.

Southeast Asia 3D Bioprinting Market Size

Southeast Asia's 3D bioprinting market is estimated at US$ 70 million in 2026. Singapore leads regional development through the Agency for Science, Technology and Research (A*STAR), the National University of Singapore, and Nanyang Technological University, which conduct bioprinting and tissue engineering research supported by the RIE2025 plan, with a budget of about S$ 25 billion. Thailand and Malaysia are expanding their medical device and biomaterial manufacturing capabilities, while growing hospital networks across the region create opportunities for bioprinted wound care and orthopedic applications.

Government incentives for biomedical manufacturing, expanding medical tourism, and regional trade integration under the Association of Southeast Asian Nations (ASEAN) further support long-term market growth. Cross-border research collaborations and increasing investment in healthcare infrastructure also strengthen the regional bioprinting ecosystem.

Competitive Landscape

The global 3D bioprinting market is fragmented, with specialized bioprinter manufacturers, biomaterial suppliers, and therapeutic developers competing alongside diversified additive manufacturing and life sciences companies. BICO Group AB, through its CELLINK business, 3D Systems Corporation, RegenHU Ltd., and Inventia Life Science Pty Ltd. compete through their bioprinting platforms and integrated technology offerings. Meanwhile, Stratasys Ltd. and Merck KGaA leverage their expertise in materials, manufacturing, and life sciences to expand their presence in the market.

Leading companies differentiate their offerings through validated printer-bioink combinations, software-enabled printing workflows, and quality management systems designed to support clinical applications.

Competitive strategies include acquisitions, such as 3D Systems Corporation's acquisition of Allevi, and strategic pharmaceutical collaborations, including the partnership between Aspect Biosystems Ltd. and Novo Nordisk. Market participants are also expanding business models through contract bioprinting services, recurring bioink and consumable sales, and milestone-based therapeutic development partnerships. These approaches support a gradual shift from one-time equipment sales toward recurring revenue streams and higher-value commercial opportunities across the bioprinting value chain.

Key Industry Developments

  • In April 2025, the U.S. Food and Drug Administration unveiled a roadmap to reduce and eventually replace animal testing requirements for monoclonal antibodies, favoring organoids, organ-on-chip systems, and human cell-based assays. The shift is expected to benefit bioprinted tissue model providers such as Organovo Holdings, Inc., CELLINK and Inventia Life Science Pty Ltd. The announcement follows the FDA Modernization Act 2.0 and encourages sponsors to submit human cell-based data in regulatory filings.
  • In January 2025, Aspect Biosystems Ltd. announced a US$ 115 million Series B financing to advance its bioprinted tissue therapeutics, including programs developed with Novo Nordisk. The funding highlights strong investor confidence in clinical-stage bioprinting and supports expansion of its manufacturing platform and pipeline. The financing follows the April 2023 partnership structure, which included an upfront payment and milestone-based incentives for bioprinted therapeutics.

Companies Covered in 3D Bioprinting Market

  • CELLINK (BICO Group AB)
  • Organovo Holdings, Inc.
  • 3D Systems Corporation
  • Stratasys Ltd.
  • RegenHU Ltd.
  • Aspect Biosystems Ltd.
  • Poietis
  • Advanced Solutions Life Sciences, LLC
  • Allevi, Inc. (3D Systems)
  • Inventia Life Science Pty Ltd.
  • ROKIT Healthcare, Inc.
  • Merck KGaA
  • CollPlant Biotechnologies Ltd.
  • United Therapeutics Corporation
Frequently Asked Questions

The global 3D bioprinting market size is estimated at US$ 3.1 billion in 2026 and is projected to reach US$ 5.9 billion by 2033, expanding at a CAGR of 9.6% between 2026 and 2033.

Demand for 3D bioprinting is primarily driven by the persistent shortage of transplantable organs and the growing shift toward human-relevant drug testing models. Rising public funding for biofabrication, expanding regenerative medicine research, and pharmaceutical R&D investments provide additional market momentum.

North America is likely to lead the 3D bioprinting market, accounting for an estimated 39% share in 2026, supported by substantial NIH funding, an established biotechnology sector, and regulatory initiatives encouraging human-relevant testing.

The key market opportunities lie in bioinks and pharmaceutical partnerships. Strategic collaborations, such as the partnership between Aspect Biosystems Ltd. and Novo Nordisk, further highlight opportunities in bioprinted therapeutics. Additionally, rising demand for regenerative medicine creates immense opportunities for bioprinter, biomaterial, and software providers.

Key players in the market include CELLINK (BICO Group AB), Organovo Holdings, Inc., 3D Systems Corporation, Stratasys Ltd., RegenHU Ltd., Aspect Biosystems Ltd., Poietis, Advanced Solutions Life Sciences, LLC, Inventia Life Science Pty Ltd., ROKIT Healthcare, Inc., Merck KGaA, CollPlant Biotechnologies Ltd., and United Therapeutics Corporation.

UK

Corporate Office

Persistence Research & Consultancy Services Limited

Company Number : 15310893

Second Floor, 150 Fleet Street,London, EC4A 2DQ.

+44 203-837-5656
USA

Regional Office

Persistence Market Research

108 W 39th Street, Ste 1006,PMB2219, New York, NY 10018

+1 646-878-6329
India

Global Research centre

Persistence Market Research Private Limited

CIN : U74900PN2014PTC153163

6th Floor, Teerth Technospace, Teerth Realties, Office No. B- 604, Baner, Pune, Maharashtra 411045

Copyright © 2026 Persistence Market Research. All Rights Reserved

Connect With Us -